Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Daewon Pharmaceutical Co., Ltd (003220) Stock Price & Analysis

003220 Stock Chart & Stats

₩8,060.00₩30.00(0.37%)
At close: 3:30 PM GMT+9
₩7.75K₩8K₩8.25K₩8.5KAug 10Aug 24Sep 7Sep 21Oct 6Oct 19Nov 2
Day’s Range
KRW 7,970.00 - KRW 8,320.00
52-Week Range
KRW 7,060.00 - KRW 13,670.00
Previous Close
KRW 8,030.00
Volume
N/A
Average Volume (3M)
176.04K
Market Cap
KRW 175.08B
Enterprise Value
KRW 307.33B
Total Cash (Recent Filing)
KRW 66.18B
Total Debt (Recent Filing)
KRW 189.15B
Price to Earnings (P/E)
63.1
Beta
-0.03
Next Earnings
Nov 12, 2026 (Est.)
EPS Estimate
N/A
Last Dividend Ex-Date
Dec 29, 2025
Dividend Yield
3.10%

Bulls Say, Bears Say

Bulls Say

Strong Revenue Growth

The company is experiencing substantial top-line acceleration, indicating stronger sales across its pharmaceutical portfolio and distribution channels. If maintained, this growth can expand operating scale, support broader market reach, and provide a larger revenue base for restoring profitability over the next several quarters.

Solid Gross Margin

A gross margin near 45% shows that the underlying product portfolio retains meaningful economics before operating expenses. This provides a foundation for earnings recovery if the company can control its operating cost base and convert strong revenue growth into sustainable operating profit.

Manageable Leverage

Debt remains manageable relative to equity, limiting immediate balance-sheet pressure and preserving some flexibility for ongoing pharmaceutical operations and development. Stable equity and sector-appropriate leverage give the company capacity to address profitability issues without an evidently excessive debt burden.

Bears Say

Negative Operating Profitability

Negative EBIT indicates that current operating costs exceed the profit generated by the business despite rapid revenue growth. This weakens earnings quality and shows that sales expansion is not yet translating into durable operating leverage, making margin recovery a central execution requirement.

Weak Free Cash Flow

Small and declining free cash flow limits internally generated funds available for research, investment, debt service, and shareholder returns. The history of inconsistency, including negative free cash flow in 2024, indicates that reported business activity is not reliably converting into surplus cash.

Compressed Returns

Very low return on equity suggests that the company is currently using its capital inefficiently, reducing the economic benefit of continued revenue expansion. With leverage higher than in prior years, weak returns also leave less room for balance-sheet improvement unless profitability strengthens.

Daewon Pharmaceutical Co., Ltd News

003220 FAQ

What was Daewon Pharmaceutical Co., Ltd’s price range in the past 12 months?
Daewon Pharmaceutical Co., Ltd lowest stock price was ₩7060.00 and its highest was ₩13670.00 in the past 12 months.
What is Daewon Pharmaceutical Co., Ltd’s market cap?
Daewon Pharmaceutical Co., Ltd’s market cap is ₩175.08B.
When is Daewon Pharmaceutical Co., Ltd’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Daewon Pharmaceutical Co., Ltd’s earnings last quarter?
Daewon Pharmaceutical Co., Ltd released its earnings results on Aug 07, 2026. The company reported ₩187.921 earnings per share for the quarter.
Is Daewon Pharmaceutical Co., Ltd overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Daewon Pharmaceutical Co., Ltd pay dividends?
Daewon Pharmaceutical Co., Ltd pays a ― dividend of ₩250 which represents an annual dividend yield of 3.1%. See more information on Daewon Pharmaceutical Co., Ltd dividends here
What is Daewon Pharmaceutical Co., Ltd’s EPS estimate?
Daewon Pharmaceutical Co., Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Daewon Pharmaceutical Co., Ltd have?
Daewon Pharmaceutical Co., Ltd has 22,427,584 shares outstanding.
What happened to Daewon Pharmaceutical Co., Ltd’s price movement after its last earnings report?
Daewon Pharmaceutical Co., Ltd reported an EPS of ₩187.921 in its last earnings report. Following the earnings report the stock price went up 4.75%.
Which hedge fund is a major shareholder of Daewon Pharmaceutical Co., Ltd?
Currently, no hedge funds are holding shares in KR:003220
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology